HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $37 price target on the stock.
December 18, 2023 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reaffirmed a Buy rating on Viridian Therapeutics with a $37 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $37 price target by a reputable analyst could lead to increased investor confidence in VRDN, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100